###### Key questions

What is already known about this subject?
=========================================

-   Following percutaneous coronary intervention (PCI) for acute coronary syndromes, rise in endothelin-1 (ET-1) levels, a potent vasoconstrictor produced by the vascular endothelium, has been proposed as a potential mediator of reperfusion injury and 'no reflow' phenomenon. Previously, Adlbrecht *et al* randomly assigned patients to receive intravenous BQ-123 at the onset of primary PCI for ST elevation myocardial infarction and demonstrated improved microvascular function using cardiac MRI at 6 days after PCI and smaller infarct sizes.

What does this study add?
=========================

-   In this study, we demonstrated the effect of BQ-123, a selective endothelin A (ET~A~) receptor antagonist, on coronary blood flow velocity in patients undergoing PCI for non-ST elevation acute coronary syndromes (NSTACS). Also, changes in creatine kinase isoenzyme MB post-PCI were noted to be significantly lower in the BQ-123 group compared to placebo group.

How might this impact on clinical practice?
===========================================

-   Adjunctive use of ET~A~ antagonist during PCI for NSTACS may augment myocardial perfusion and minimise procedure-induced myocardial ischaemia.

Introduction {#s1}
============

Endothelin-1 (ET-1) is a potent vasoconstrictor produced by the vascular endothelium and in the human heart.[@R1] [@R2] ET-1 mainly acts through two receptors: endothelin receptor type A (ET~A~) and type B. ET~A~ has high affinity for ET-1 and is highly expressed in vascular smooth muscle cells and in myocardium.[@R1] ET-1 contributes to maintenance of basal coronary artery tone in humans with or without coronary artery disease,[@R3] and its expression is increased in atherosclerotic coronary arteries.[@R4] [@R5] Prior studies have shown that, in response to mechanical pressure and stretch during angioplasty, there is an acute rise in ET-1 levels.[@R6] [@R7] Following percutaneous coronary intervention (PCI) for acute myocardial infarction (MI), this rise in ET-1 levels has been proposed as a potential mediator of reperfusion injury and 'no reflow' phenomenon due to its powerful vasoconstrictor properties.[@R8]

Treatment of high-risk patients with acute coronary syndromes, including unstable angina and non-ST elevation myocardial infarction (NSTEMI) (non-ST elevation acute coronary syndromes (NSTACS)), by PCI is focused mainly on achieving epicardial coronary artery patency. However, in spite of restoring thrombolysis in myocardial infarction (TIMI) grade 3 flow in the epicardial coronary vessels, many patients with NSTACS do not regain normal microvascular perfusion.[@R9] [@R10] This phenomenon of failure to achieve adequate tissue perfusion, when angiographically detectable, is referred to as 'no reflow', and it is believed to occur as a result of microvascular damage or intramyocardial oedema due to ischaemia.[@R11] Failure to restore normal microvascular perfusion is associated with progressive myocardial ischaemia resulting in larger infarcts, lethal ventricular arrhythmias, cardiac failure, cardiogenic shock and death.[@R12] [@R13] Quantitative assessment of microvascular injury can help predict prognosis after acute MI.[@R14] [@R15] Understanding the pathophysiology of myocardial malperfusion is important in developing novel therapies. The precise mechanisms responsible for myocardial malperfusion are unknown, but abnormal function of the microcirculation is likely to be a key component.

We hypothesised that the endogenous endothelin system contributes to microvascular dysfunction and impaired myocardial reperfusion following successful PCI for NSTACS and that endothelin receptor antagonism will improve microvascular flow. The aim of the study was to provide new insights into the humoral regulation of the microcirculation in this patient population. Specifically, we assessed the acute effect of adjunctive BQ-123, a selective ET~A~ receptor antagonist, on coronary microvascular blood flow immediately following PCI.

Methods {#s2}
=======

Study population {#s2a}
----------------

The study was a prospective, double-blind, randomised, placebo-controlled trial. Twenty-three consecutive patients admitted to the Mayo Clinic for NSTACS between August 2006 and December 2008 were enrolled in the study ([figure 1](#OPENHRT2016000428F1){ref-type="fig"}). Inclusion criteria included age ≥ 18 years, a clinical diagnosis of NSTEMI or unstable angina and requiring clinically indicated PCI. Patients were excluded from the study if they had one or more of the following: systemic hypotension (systolic blood pressure \< 90 mm Hg); heart failure or known ejection fraction \< 30%; left main disease; culprit lesion is in a saphenous vein graft; 100% occlusion of the culprit vessel or culprit is an ostial right coronary stenosis; currently enrolled in another active cardiovascular investigational study; severe endocrine, hepatic and renal disorders; pregnancy or lactation; inability to provide consent; Federal Medical Center inmates; and inability or unwillingness to provide informed consent.

![Study design. Patient enrolment, randomisation and study protocol. NSTEMI, non-ST elevation myocardial infarction; PCI, percutaneous coronary intervention.](openhrt2016000428f01){#OPENHRT2016000428F1}

Protocol {#s2b}
--------

After screening for inclusion and exclusion criteria and collecting baseline laboratory blood test data, all of the patients were randomised by a nurse coordinator to either a placebo or the selective ET~A~ receptor antagonist BQ-123 (Bachem, Germany). A selective intracoronary infusion of either 300 nmol/min of BQ-123 or the placebo (saline) was administered for 20 min into the culprit artery, proximal to the lesion, immediately prior to PCI ([figure 1](#OPENHRT2016000428F1){ref-type="fig"}). In the event of a very proximal culprit lesion or if selective infusion was precluded, non-selective infusion was attempted. Anti-ischaemic, antiplatelet and anticoagulant therapy before and following randomisation was administered at the discretion of the primary physician and the interventional cardiologist. The following parameters were assessed at baseline and after completion of PCI: heart rate, systolic blood pressure, coronary artery diameter, coronary blood flow (CBF), coronary vascular resistance (CVR) and coronary flow reserve (CFR) in response to intracoronary adenosine in the culprit vessel. CFR was the primary end point. Coronary angiograms were analysed by investigators who were blinded to the assigned treatment.

Coronary angiography and percutaneous coronary intervention {#s2c}
-----------------------------------------------------------

Coronary angiography and PCI were performed in patients who met the recruitment criteria and after obtaining informed consent. Adjunctive cardiovascular medications were continued as clinically indicated. Routine baseline blood work was conducted pre-PCI. A standard percutaneous right femoral approach was used for all of the patients. Diagnostic coronary angiography was performed using 5 F Judkins catheter. The sheath was upsized to either 6 or 7 F for the PCI. A bolus of 70--100 U/kg intravenous unfractionated heparin was administered, with additional doses given to maintain a therapeutic ACT (250--300 s). After guide engagement, a microcatheter was placed in the culprit artery for the infusion. On completion of the infusion, PCI was performed using techniques, equipment and practices standard to the Mayo Clinic catheterisation laboratory using either a bare metal or drug-eluting stent.[@R16] All angiographically significant lesions (≥70% stenosis) in the culprit artery were treated.

Coronary Doppler study {#s2d}
----------------------

Following successful PCI, the coronary guidewire was replaced by a 0.014 inches Doppler guide wire (FloWire, Volcano Incorporated). The wire was positioned in the proximal segment of the target vessel to measure the average peak velocity (APV), systolic and diastolic peak velocities at baseline and during hyperaemia with intracoronary adenosine. Adenosine (Fujisawa, Deerfield, Illinois, USA), an endothelium-independent vasodilator, was administered in incremental bolus doses (30--72 µg in the left main or 18--24 µg in the right coronary artery) to achieve maximal APV. CFR was calculated using the formula: CFR=Hyperaemic APV/baseline APV.[@R17] Similarly, CBF and CVR were calculated using the following formulae:[@R18] [@R19]

Quantitative coronary angiography {#s2e}
---------------------------------

Quantitative measurements of the coronary arteries were obtained using a computer-based image analysis system (Medis, NC) in the Center for Coronary Physiology and Imaging as mentioned previously. End-diastolic frames, which show segments without foreshortening or overlap from adjacent arteries, were chosen to measure coronary artery diameters 5 mm from the tip of the Doppler wire in an angiographically smooth proximal segment of the culprit vessel. After appropriate calibration of the guide catheter, image calibration was carried out using a manual edge detection programme to determine the arterial diameters.

Cardiac biomarkers {#s2f}
------------------

Creatine kinase isoenzyme MB (CK-MB) and cardiac troponin T (cTnT) levels were systematically measured from blood samples collected before intervention, and at 8 and at 16 hours after the procedure, as part of standard clinical practice. Biomarker determinations were performed in the Mayo clinical chemistry laboratory by the mass-determination methods (E Modular CK-MB and cTnT methods, Roche Diagnostics Corporation, Indianapolis, Indiana, USA). Normal reference values for CK-MB are \<6.7 ng/mL in men and \<3.8 ng/mL in women[@R20] and for cTnT are \<0.01 ng/mL.[@R21]

Statistical analysis {#s2g}
--------------------

All statistical analyses were performed using JMP V.9 software (SAS Institute, Cary, North Carolina, USA). Continuous variables were expressed as median with IQR or mean±SD where appropriate. Power calculation was based on a prior similar study in which post-PCI CFR was reported to be 2.35±0.39.[@R22] Pharmacological interventions with a vasodilator following PCI improved CFR by over 0.3. Assuming that the common SD of CFR was no more than 0.60, we estimated that 25 patients would be required in each group, providing 80% power to detect a mean difference of 0.49 in CFR between the treatment and control groups.[@R22] Categorical variables were expressed in percentages, and the differences between the groups were measured by Fisher\'s exact test or χ^2^ test. Group differences were analysed by t-test or Wilcoxon signed-rank test for normal and non-normal distributions of variables, respectively. All of the hypotheses tested were two-way, and a p value of \<0.05 was considered statistically significant. p Values for pretreatment comparisons are provided for descriptive purposes. Since groups were assigned by randomisation, all prerandomised measures must be independent of group assignment.

Results {#s3}
=======

Baseline and PCI characteristics {#s3a}
--------------------------------

Both of the study groups were similar with respect to age, gender, body mass index, type of NSTACS, history of prior MI history of prior PCI and conventional cardiovascular risk factors ([table 1](#OPENHRT2016000428TB1){ref-type="table"}).

###### 

Baseline clinical characteristics

  Variable, n (%)            Placebo (n=11)             Drug (n=11)                p Value\*
  -------------------------- -------------------------- -------------------------- -----------
  Age, years                 64±12.5                    64.5±11.2                  0.97
  Male gender                9 (82)                     7 (64),                    0.34
  BMI, kg/m^2^               31±6.5                     30.4±5.1                   0.95
  Diagnosis                  UA=6 (55), NSTEMI=5 (45)   UA=3 (27), NSTEMI=8 (73)   0.19
  History of MI              2 (18.2)                   1 (9.1)                    0.53
  Prior PCI                  2 (18.2)                   3 (27.3)                   0.61
  Family history of CAD      9 (81.8)                   5 (45.5)                   0.19
  Current smoking            3 (27.3)                   1 (9.1)                    0.44
  Hyperlipidaemia            10 (91)                    6 (54.6)                   0.058
  Diabetes mellitus          2 (18.2)                   3 (27.3)                   0.61
  Hypertension               9 (81.8)                   8 (72.7)                   0.61
  Total cholesterol, mg/dL   183±48.5                   177.8±41.2                 0.79
  TGs, mg/dL                 105 (88, 164)              104 (61, 195)              0.65
  LDL cholesterol, mg/dL     111±46                     102±43                     0.63
  HDL cholesterol, mg/dL     45.5±9.4                   44.7±13                    0.87
  Creatinine (mg/dL)         1.0 (0.9, 1.1)             1.1 (0.8, 1.2)             0.59
  *Baseline medications*                                                           
  Aspirin                    7 (64)                     5 (45)                     0.39
  Clopidogrel                1 (9)                      3 (27)                     0.27
  β-Blockers                 3 (27)                     6 (55)                     0.19
  ACE inhibitors             4 (36)                     3 (27)                     0.65
  Statins                    4 (36)                     5 (45)                     0.67
  CCBs                       2 (18)                     0 (0)                      0.14
  Warfarin                   0 (0)                      1 (9)                      0.31
  Digoxin                    0 (0)                      1 (9)                      0.31
  Diuretics                  2 (18)                     2 (18)                     1.00
  Oral hypoglycaemics        2 (18)                     3 (27)                     0.61

\*p Values for pretreatment comparisons are provided for descriptive purposes. Data are expressed as mean±SD, median (IQR) or number (percentage).

ACE, ACE inhibitors; BMI, body mass index; CAD, coronary artery disease; CCB, calcium channel blocker; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MI, myocardial infarction; NSTEMI, non-ST elevation myocardial infarction; PCI, percutaneous coronary intervention; TG, triglycerides; UA, unstable angina.

Except for one (unable to cross lesion with a wire---probable chronic occlusion), procedural success was achieved in all of the patients (n=22) with postprocedural TIMI 3 flow. [Table 2](#OPENHRT2016000428TB2){ref-type="table"} demonstrates angiographic and procedural characteristics in both of the groups.

###### 

Angiographic and procedural characteristics

  Variable, n (%)                               Placebo (n=11)                     Drug (n=11)                         p Value\*
  --------------------------------------------- ---------------------------------- ----------------------------------- -----------
  Number of diseased vessels (\>70% stenosis)   1=4 (36)                           1=5 (45.5)                          0.80
  2=5 (46)                                      2=5 (45.5)                                                             
  3=2 (18)                                      3=1 (9)                                                                
  Culprit vessel                                LAD=3 (27)                         LAD=6 (55)                          0.43
  LCx=3 (27)                                    LCx=2 (18)                                                             
  RCA=5 (46)                                    RCA=3 (27)                                                             
  Vessels treated                               1=8 (73)                           1=10 (91)                           0.27
  2=3 (27)                                      2=1 (9)                                                                
  GP IIb/IIIa inhibitor use                     7 (64)                             7 (64)                              1.00
  Clopidogrel before PCI                        1 (9)                              2 (18)                              0.53
  Clopidogrel during PCI                        10 (91)                            9 (82)                              0.53
  Days from symptom onset to PCI†                                                                                      0.61
   1                                            3 (27)                             3 (30)                              
   2                                            2 (18)                             2 (20)                              
   3                                            1 (9)                              2 (20)                              
   4                                            1 (9)                              1 (10)                              
   5 or more                                    4 (36)                             2 (20)                              
  ACC/AHA lesion severity grade                 A=1 (9.1), B=9 (81.8), C=1 (9.1)   A=1 (9.1), B=7 (63.6), C=1 (27.3)   0.54
  Culprit lesion stenosis, %                    88±8                               85±9                                0.56
  Stent type                                    BMS=4 (36)                         BMS=0                               0.027
  DES=7 (64)                                    DES=11 (100)                                                           
  Maximum stent diameter, mm                    3.5 (2.5, 4)                       2.75 (2.5, 3)                       0.051
  Total stent length, mm                        13 (13, 18)                        13 (13, 18)                         0.73
  Max stent deployment pressure, mm Hg          15±2.5                             14±2.3                              0.19
  Baseline LVEF, %                              57±7.4                             60±7                                0.43

Data are expressed as number (percentage), median (IQR) and mean±SD.

\*p Values for pretreatment comparisons are provided for descriptive purposes.

†Days from symptom onset to PCI were unknown for one participant in the drug group.

ACC/AHA, American College of Cardiology/American Heart Association; BMS, bare metal stent; DES, drug-eluting stent; GP, glycoprotein; LAD, left anterior descending artery; LCx, left circumflex artery; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; RCA, right coronary artery.

Haemodynamic parameters {#s3b}
-----------------------

No significant changes in blood pressure and heart rate were observed between the two groups following randomisation and following PCI ([table 3](#OPENHRT2016000428TB3){ref-type="table"}).

###### 

Haemodynamics

  Variable          Placebo (n=11)   Drug (n=11)   p Value\*
  ----------------- ---------------- ------------- -----------
  Heart rate, bpm                                  
   Predrug          66±13            66±9          0.98
   Postdrug         61±12            64±7          0.38
   Post-PCI         70±19            71±7          0.82
  SBP, mm/Hg                                       
   Predrug          126±22           121±32        0.67
   Postdrug         123±22           121±27        0.83
   Post-PCI         127±36           116±25        0.43
  DBP, mm/Hg                                       
   Predrug          74±13            68±13         0.25
   Postdrug         70±14            66±10         0.52
   Post-PCI         71±20            64±12         0.30
  MAP, mm/Hg                                       
   Predrug          96±16            90±18         0.42
   Postdrug         91±17            89±14         0.82
   Post-PCI         95±26            85±15         0.29

\*p Values for pretreatment comparisons are provided for descriptive purposes. Data are expressed as mean±SD.

DBP, diastolic blood pressure; MAP, mean arterial pressure; PCI, percutaneous coronary intervention; SBP, systolic blood pressure.

Doppler flow parameters {#s3c}
-----------------------

In univariate analysis, mean APV immediately after PCI was significantly higher in the BQ-123 group compared with the placebo group (p=0.03) ([table 4](#OPENHRT2016000428TB4){ref-type="table"} and [figure 2](#OPENHRT2016000428F2){ref-type="fig"}). Also, APV after intracoronary infusion of adenosine was higher in the BQ-123 group, but of borderline statistical significance (p=0.09). CFR was not significantly different between the groups ([table 4](#OPENHRT2016000428TB4){ref-type="table"}). CBF was higher and CVR was lower, immediately after PCI, in the BQ-123-treated group compared with placebo group; however, these differences were not statistically significant ([table 4](#OPENHRT2016000428TB4){ref-type="table"}).

###### 

Coronary haemodynamic variables

  Variable, n (%)                       Placebo (n=11)      Drug (n=11)        p Value
  ------------------------------------- ------------------- ------------------ ---------
  Immediate post-PCI APV, cm/s          19 (9, 26)          30 (20, 37)        0.030\*
  Immediate post-PCI DSVR               1.7 (1.3, 3.5)      2 (1.4, 3.2)       0.93
  CBF immediately after PCI, mL/min     53 (31, 94)         80 (43, 119)       0.19
  CVR immediately after PCI, mm Hg/mL   2.1 (1, 2.6)        1.0 (0.8, 1.7)     0.15
  Adenosine APV, cm/s                   46 (34, 64)         56 (48, 72)        0.090
  Adenosine DSVR                        1.9±0.9             1.6±0.5            0.24
  Post-adenosine CBF, mL/min            120 (84, 242)       127 (104, 313)     0.55
  Post-adenosine CVR, mm Hg/mL          0.65 (0.38, 1.55)   0.59 (0.35, 0.8)   0.50
  Max CFR                               2.5 (1.8, 3)        2.1 (1.6, 2.9)     0.39

\*p\<0.05.

Data are expressed as median (IQR) or mean±SD.

APV, average peak velocity; CBF, coronary blood flow; CFR, coronary flow reserve; CVR, coronary vascular resistance; DSVR, diastolic/systolic velocity ratio.

![Average peak velocity. APV (cm/s) in drug and placebo groups immediately post-PCI and after intracoronary adenosine infusions.](openhrt2016000428f02){#OPENHRT2016000428F2}

Cardiac biomarkers {#s3d}
------------------

In the BQ-123 group, 1 (11%) out of 9 patients, who had 8-hour post-PCI cardiac biomarker measured, had elevated cTnT and CK-MB levels compared with 7 out of 9 (64%) patients in the placebo group (p=0.02 and p=0.02, respectively). Although the absolute cTnT levels in both of the groups were not significantly higher, the median levels maintained a relatively plateau trend in the BQ-123 group compared with those in the placebo group where the levels were observed to rise continuously after procedure ([table 5](#OPENHRT2016000428TB5){ref-type="table"}). Compared to pre-PCI levels, CK-MB increased post-PCI in the placebo group (p=0.05), but not in the BQ-123 group (p=0.21). Thus, the per cent changes in CK-MB from pre-PCI to post-PCI at 8 and 16 hours were significantly lower in the BQ-123 group compared with the placebo group, p=0.02 and p=0.007, respectively ([table 5](#OPENHRT2016000428TB5){ref-type="table"} and [figure 3](#OPENHRT2016000428F3){ref-type="fig"}A). A similar trend was seen for cTnT levels, but these differences were not statistically significant ([figure 3](#OPENHRT2016000428F3){ref-type="fig"}B).

###### 

Cardiac biomarker characteristics

  Cardiac biomarkers                             Placebo (n=11)      Drug (n=11)          p Value
  ---------------------------------------------- ------------------- -------------------- ---------
  *Troponin T (ng/mL)*                                                                    
  Immediate pre-PCI                              0.03 (0.01, 0.13)   0.04 (0.01, 0.28)    0.44
  8 hours                                        0.07 (0.01, 0.15)   0.045 (0.03, 0.16)   0.67
  16 hours                                       0.14 (0.01, 0.18)   0.06 (0.02, 0.45)    0.84
  \% Change from immediate pre-PCI to 8 hours    35 (0, 300)         25 (−6, 68)          0.34
  \% Change from immediate pre-PCI to 16 hours   96 (0, 220)         33 (0, 73)           0.18
  \% Change from 8 to 16 hours                   0 (−7, 45)          0 (−4, 3)            0.47
  *CK-MB (ng/mL)*                                                                         
  Immediate pre-PCI                              2.8 (2, 3.9)        5.5 (2.9, 10.5)      0.11
  8 hours                                        3.8 (2.8, 9.1)      4.8 (2.7, 7.7)       0.91
  16 hours                                       11 (3.03, 16.18)    4.4 (2.8, 8.7)       0.23
  \% Change from immediate pre-PCI to 8 hours    26 (−15, 134)       −17 (−26, −10)       0.020\*
  \% Change from immediate pre-PCI to 16 hours   107 (2, 446)        −17 (−38, 14)        0.007\*
  \% Change from 8 to 16 hours                   27 (3, 82)          −3 (−18, 14)         0.11

\*p\<0.05.

Data are expressed as median (IQR).

CK-MB, creatine kinase isoenzyme MB; PCI, percutaneous coronary intervention.

![(A) Percentage change in CK-MB levels. Percentage change in CK-MB levels from the time of PCI to 8 and 16 hours post-PCI. (B) Percentage change in cTnT levels. Percentage change in cTnT from the time of PCI to 8 and 16 hours after PCI.](openhrt2016000428f03){#OPENHRT2016000428F3}

Dosage and safety of BQ-123 {#s3e}
---------------------------

No adverse effects were reported during or after intracoronary infusion of 300 nmol/min of BQ-123.

Discussion {#s4}
==========

The present study among NSTACS patients demonstrates that administration of intracoronary BQ-123, a selective ET~A~ antagonist, is associated with higher CBF velocity and diminished cardiac biomarker elevation following PCI. Moreover, it establishes the safety of selective ET~A~ receptor antagonism with BQ-123 during percutaneous revascularisation in NSTACS.

To the best of our knowledge, this is the first study to assess the role of endogenous ET-1 during PCI in NSTACS. We observed that BQ-123 infusion was associated with a 50% higher blood flow velocity, immediately after PCI, compared to those receiving placebo. Doppler-derived measures of blood flow velocity have been shown to correlate with adverse cardiac outcomes following MI.[@R14] [@R15] In our study, although not statistically significant, the CFR post-PCI, in the absence of an angiographically significant epicardial stenosis, was lower in the BQ-123-treated patients. This may seem counterintuitive, but we believe that it can be accounted for by the higher resting blood flow in the BQ-123-treated group. Potentially, delayed measurements may have yielded different results once autoregulation would have reduced the resting blood flow. Our findings suggest that ET-1 is a mediator of PCI-related microvascular injury and impaired blood flow.

Plasma ET-1 levels are known to rise acutely following an MI.[@R23] The highest ET-1 expression in atherosclerotic arteries occurs in active plaques and in response to mechanical stretch during PCI.[@R6] [@R7] ET-1 levels peak at ∼1 hour post-PCI, and we hypothesise that vascular injury is likely to occur in this time window.[@R24] Adjunctive ET~A~ antagonism during PCI likely diminishes vasoconstriction, by inhibiting the direct and indirect (via augmenting angiotensin II, norepinephrine and serotonin) effects of ET-1.

Endothelin antagonists have been approved for the treatment of pulmonary hypertension and have been investigated in heart failure. BQ-123 is a peptide consisting of five amino acids. Several clinical studies in coronary and peripheral circulation with BQ-123 have been published.[@R27] Dosing of BQ-123 in the present study was based on the observation that in patients with angiographically normal coronary arteries and in those with mild coronary atherosclerosis, intracoronary infusion of BQ-123, at doses ranging from 40 to 300 nmol/min, dilates the epicardial and microvessels and improves endothelial dysfunction.[@R3] [@R28] Our work extends the findings of Adlbrecht *et al*, who randomly assigned patients to receive intravenous BQ-123 at 400 nmol/min or placebo over 60 min, starting at the onset of primary PCI for ST elevation myocardial infarction (STEMI). Improved microvascular function was detected in the BQ-123 group using cardiac MRI at 6 days after PCI. This was associated with smaller enzymatic infarct sizes.[@R31] Also, at 6 months, left ventricular ejection fraction was noted to be significantly higher in the BQ-123 group compared to the placebo group (63% (58--69) vs 59% (51--66); p=0.047).

Elevations in cardiac biomarkers in NSTACS identify patients with severe and complex coronary lesions and a greater thrombus burden.[@R32] However, more recent investigations in NSTACS patients have demonstrated that elevations in cardiac biomarkers are also a marker of impaired myocardial perfusion.[@R33] Accordingly, in the present study, the fact that improved parameters of CBF with BQ-123 were associated with a diminished increase of CK-MB and troponin following PCI suggests that the augmented microvascular perfusion is likely to lead to clinically meaningful benefits. Our findings mirror those of Adlbrecht *et al*[@R31] who reported smaller infarct sizes in STEMI patients treated with BQ-123 during primary PCI.

Studies have previously reported that in patients undergoing PCI, elevated cardiac biomarkers are associated with higher subsequent coronary events and mortality. Furthermore, the risk of adverse outcomes increases with any level of rise in cardiac enzymes.[@R34]

Limitations {#s4a}
-----------

Our study is subject to several limitations. First, the small size raises the distinct possibility of a statistical type 2 error with differences not being detected in baseline characteristics and/or indices of coronary haemodynamics and flow. The inability to reach the target recruitment was to large extent due to the insufficient supply of the study drug BQ-123 during the study period. This factor limits the strength of our conclusions regarding the role of endothelin in microvascular dysfunction post-PCI. Further large-scale, randomised clinical trials are required to define the role of endothelin in microvascular dysfunction post-PCI in patients with NSTACS and determine the efficacy of intraprocedural administration of selective ET~A~ antagonists in preventing impaired myocardial perfusion. Second, lack of pre-PCI coronary flow parameters limits the precise assessment of the effect of BQ-123 on post-PCI measurements. However, this was not feasible using Doppler techniques since the presence of an epicardial stenosis precludes assessment of microvascular blood flow. Newer techniques such as the index of microvascular resistance that can be used even in the presence of epicardial stenosis should be incorporated in future studies. Third, the use of the Doppler wire and cardiac biomarkers only to assess the microcirculation and myocardial injury, respectively, has inherent limitations. Our findings would be strengthened had we concomitantly used additional techniques to assess myocardial perfusion and infarct size. However, our study design was based on the most applicable and readily available techniques. While baseline haemodynamic, angiographic and procedural variables were comparable in the two groups, stent diameter was smaller in the BQ-123 group, and this was of borderline statistical significance. This may have potentially impacted our results. Finally, our study did not meet the primary end point, and hence our conclusions are derived from secondary end points with inherent potential for bias from a study of small sample size.

Conclusions {#s4b}
-----------

The current study demonstrates that adjuvant administration of ET~A~ receptor antagonist during PCI is safe and results in improved microvascular flow patterns in association with improved tissue-level myocardial perfusion. The study further supports the role of ET pathway in the regulation of myocardial blood flow following PCI. Further large-scale, randomised studies are required to define the role of endothelin as the common denominator of elevated cardiac biomarker levels and abnormal coronary Doppler flow parameters and also develop a new therapeutic strategy to prevent PCI-related myocardial injury.
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